The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

NEW YORK – BlossomHill Therapeutics on Wednesday said it has begun treating lung cancer patients with EGFR- or HER2-mutated tumors with its OMNI-EGFR inhibitor BH-30643 in a Phase I/II trial. The ...

NEW YORK – By the end of a controversial workshop Thursday on whether to test patients for genetic abnormalities that put them at risk of severe chemotherapy-related toxicities, oncologists seemed ...

The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.